Qube Research & Technologies LTD Supernus Pharmaceuticals, Inc. Transaction History
Qube Research & Technologies LTD
- $65.7 Billion
- Q3 2024
A detailed history of Qube Research & Technologies LTD transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 100,964 shares of SUPN stock, worth $3.85 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100,964
Previous 160,172
36.97%
Holding current value
$3.85 Million
Previous $4.28 Million
26.52%
% of portfolio
0.0%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding SUPN
# of Institutions
283Shares Held
60.6MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$397 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$234 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$195 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$110 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$100 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.04B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...